• Abbisko Cayman entered a strategic collaboration with AstraZeneca to co-develop an IO-TKI regimen for non-small cell lung cancer.
• The partners will run a multicenter, open-label Phase I/II trial of lumipodlin (ABSK043) with Tagrisso (osimertinib).
• The study targets EGFR-mutated, PD-L1-positive locally advanced or metastatic NSCLC.
• China’s NMPA cleared the IND for the combination study on May 20, 2026.
• Abbisko will lead Phase II; Abbisko and AstraZeneca will share clinical trial responsibilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260702-12225227), on July 02, 2026, and is solely responsible for the information contained therein.